ClearNote Health
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ClearNote Health - overview
Established
2016
Location
San Mateo, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2016, ClearNote Health, formerly known as Bluestar Genomics Inc. , operates as a biotechnology company that develops next generation epigenomic approaches to detect deadly cancers, like pancreatic, early when curative therapies are possible. In May 2026, ClearNote Health raised USD 52 million in venture funding from Pathology Asia ClearNote Health combines novel epigenomic technology with machine learning to detect early pancreatic cancer from a standard blood draw by analyzing cell-free DNA in plasma, these can be used as new biomarkers that can detect pancreatic cancer before the malignancy.
Current Investors
Prosperity Capital Management, Pathology Asia
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.clearnotehealth.com
Verticals
Artificial Intelligence
Company Stage
Series D
Total Amount Raised
Subscriber access only
ClearNote Health - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.